Department of Public Health, Graduate School, Yonsei University, Seoul, Republic of Korea.
Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
J Gastroenterol. 2017 Aug;52(8):920-928. doi: 10.1007/s00535-016-1300-3. Epub 2016 Dec 27.
Intestinal Behçet's disease (BD) is very rare, and epidemiologic data regarding BD are scarce. Moreover, there have been no population-based studies focusing on intestinal BD. We conducted a nationwide population-based study to examine the incidence and clinical course of Korean patients with intestinal BD.
We collected data on 365 patients diagnosed with intestinal BD from 2011 to 2014 using the Health Insurance Review and Assessment Services claims database. We analyzed the incidence and clinical outcomes, including cumulative rates of bowel resection, hospitalization, and medication use.
During the study period, the average annual incidence for intestinal BD was 0.18 per 10 population, and the proportion of cases with intestinal involvement was 3.9%. At 1 and 4 years after diagnosis, the cumulative rates of surgery were 5.0 and 10.9%, respectively, whereas those of hospitalization were 27.8 and 32.4%, respectively. The 1- and 4-year cumulative rates of requirements for medications were 39.8 and 49.1% for moderate- to high-dose corticosteroids, 33.6 and 42.1% for immunomodulators, and 3.5 and 6.8% for biologics, respectively. The cumulative probability of corticosteroid and immunomodulator use was higher in male than in female patients and in younger (<40 years) than in older (≥40 years) patients. However, there were no significant differences in the cumulative probabilities of surgery, hospitalization, and biologics use according to sex and age group.
The incidence of intestinal BD in Korea is quite low and has been stable in recent years.
肠型贝赫切特病(BD)非常罕见,有关 BD 的流行病学数据也很有限。此外,还没有针对肠型 BD 的基于人群的研究。我们进行了一项全国性的基于人群的研究,以研究韩国肠型 BD 患者的发病率和临床过程。
我们使用健康保险审查和评估服务索赔数据库,从 2011 年至 2014 年收集了 365 例诊断为肠型 BD 的患者的数据。我们分析了发病率和临床结果,包括肠切除术、住院和药物使用的累积率。
在研究期间,肠型 BD 的平均年发病率为 0.18/10 人口,肠型受累的比例为 3.9%。在诊断后的 1 年和 4 年时,手术的累积发生率分别为 5.0%和 10.9%,而住院的累积发生率分别为 27.8%和 32.4%。1 年和 4 年时,中到大剂量皮质类固醇、免疫调节剂和生物制剂的累积药物需求率分别为 39.8%和 49.1%、33.6%和 42.1%、3.5%和 6.8%。男性和年龄较小(<40 岁)的患者使用皮质类固醇和免疫调节剂的累积概率高于女性和年龄较大(≥40 岁)的患者。然而,手术、住院和生物制剂使用的累积概率在性别和年龄组之间没有显著差异。
韩国肠型 BD 的发病率相当低,近年来一直保持稳定。